# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Frederick Cook (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EX006-SYN
- Date: 2026-08-18
- Fictional facility: St. Posthumous Health Center
- Fictional author: Harriet Okafor-Brandt, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Six-week review of blood pressure, electrolytes and kidney function four weeks after starting hydrochlorothiazide and amlodipine. **S**

## History of present illness

Mr. Cook returns four weeks after starting hydrochlorothiazide 25 mg, amlodipine 5 mg, atorvastatin 40 mg and aspirin 81 mg. He has missed no doses. He urinates more in the mornings but has no dizziness on standing, cramps, ankle swelling, muscle aches, indigestion or bruising. His home readings over the past week average 136/82. He has had no stroke symptoms. He had the echocardiogram this morning. He signed a weekly lease for his room and is waiting for his benefits decision. **S**

| Element | Detail |
|---|---|
| Home blood pressure | Average 136/82 over the past week |
| Medicine effects | More morning urination; no dizziness, cramps, swelling, muscle aches or bleeding |
| Stroke symptoms | None |
| Social | Room settled; benefits decision pending |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest pain or ankle swelling |
| Neurological | Negative | No weakness, numbness, speech trouble, or dizziness on standing |
| Musculoskeletal | Negative | No muscle aches or cramps |
| Gastrointestinal | Negative | No indigestion or black stools |

4 systems reviewed. **S**

## Current medications

- Hydrochlorothiazide 25 mg tablet, one tablet by mouth each morning **S**
- Amlodipine 5 mg tablet, one tablet by mouth daily **S**
- Atorvastatin 40 mg tablet, one tablet by mouth daily **S**
- Aspirin 81 mg delayed-release tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 138/84 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 75.4 kg; BMI 24.6 kg/m². All vital signs are synthetic.

Sodium: 136 mmol/L; Potassium: 3.6 mmol/L; Creatinine: 1.02 mg/dL; eGFR: 82 mL/min/1.73 m². All results are synthetic.

## Change since baseline

- Sodium: 140 mmol/L at baseline, 136 mmol/L at this visit **S**
- Potassium: 4.2 mmol/L at baseline, 3.6 mmol/L at this visit **S**
- Creatinine: 0.98 mg/dL at baseline, 1.02 mg/dL at this visit **S**
- eGFR: 86 mL/min/1.73 m² at baseline, 82 mL/min/1.73 m² at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 138/84, pulse 70, weight 75.4 kg; no drop on standing |
| Neck | Soft right carotid bruit, unchanged |
| Cardiovascular | Regular rhythm; no ankle edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Essential hypertension, improving** (I10). Office 138/84 and home average 136/82, down from 154/90 before treatment but not yet below 130/80; the diuretic's full effect takes four to six weeks. Sodium 136 and potassium 3.6 mmol/L, both at the low end of normal on hydrochlorothiazide; creatinine 1.02 mg/dL, eGFR 82. Echocardiogram today: no left ventricular hypertrophy, ejection fraction about 60 percent. **S**
   - Continue hydrochlorothiazide 25 mg and amlodipine 5 mg; reassess at the next visit before adding or raising a dose.
   - Eat potassium-rich fruit and vegetables.
   - Electrolytes and a lipid panel at the next visit.
2. **Asymptomatic right internal carotid stenosis** (I65.21). No symptoms; taking atorvastatin and aspirin without side effects. **S**
   - Continue atorvastatin 40 mg and aspirin 81 mg.
   - Lipid panel and ALT at the next visit, within 12 weeks of starting.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Office blood pressure, seated, average of two readings | Every visit | Completed today | 138/84 mmHg |
| Self-management | Home blood pressure monitoring | At diagnosis and after each treatment change | Completed today | Average 136/82 over the past week |
| Laboratory | Sodium, potassium, creatinine and eGFR | Baseline; early after starting a diuretic or an ARB; then every 6 months | Completed today | Sodium 136, potassium 3.6 mmol/L, creatinine 1.02 mg/dL, eGFR 82, four weeks after starting hydrochlorothiazide |
| Laboratory | Lipid panel | Baseline; 4 to 12 weeks after starting a statin; then every 3 to 12 months | Due | Due at the next visit, ten weeks after starting atorvastatin |
| Imaging | Echocardiogram | At diagnosis of stage 2 hypertension | Completed today | No left ventricular hypertrophy; ejection fraction about 60 percent; mild aortic sclerosis |
| Medication safety | Diuretic effects: orthostatic symptoms, cramps, sodium and potassium | Early after starting, then every visit | Completed today | No orthostatic drop; sodium and potassium low-normal |
| Medication safety | Antiplatelet adherence and bleeding | Every visit | Completed today | Taking aspirin daily; no bleeding or indigestion |
| Medication safety | Statin adherence and muscle symptoms | Every visit | Completed today | No muscle symptoms |
| Self-management | Stroke warning signs (BE FAST) and calling 911 | Every visit | Completed today | No symptoms; knows the signs |
| Self-management | Re-entry social needs: housing, income, benefits, records | Every visit until settled | Completed today | Weekly lease signed; benefits pending |

## Goal progress

- Office and home blood pressure below 130/80 mmHg by four months. In progress; target 2026-10-27. **S**
- LDL cholesterol lowered by at least half on a statin. In progress; target 2026-09-29. **S**
- Knows the warning signs of stroke and to call 911 at once. Outcome by 2026-07-21: Taught and repeated back the BE FAST signs at the consultation visit. **S**
- A stable room, Social Security and Medicare in place, and a health insurance card in hand. In progress; target 2026-09-29. **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (Jones DW, et al. Hypertension 2025;82:e212-e316) (2025), American Heart Association; American College of Cardiology
- CMID: Clinical Monitoring Intelligence Database, hypertension, hyperlipidemia and stroke/TIA monographs (2026), Aether Forge
- 2024 Guideline for the Primary Prevention of Stroke: A Guideline From the American Heart Association/American Stroke Association (Bushnell C, et al. Stroke 2024;55:e344-e424) (2024), American Heart Association/American Stroke Association
- 2018 AHA/ACC Guideline on the Management of Blood Cholesterol (Grundy SM, et al. Circulation 2019;139:e1082-e1143) (2018), American Heart Association; American College of Cardiology

## Follow-up

- Twelve-week review in six weeks, with electrolytes, a lipid panel and ALT. **S**
- Next scheduled visit 2026-09-29: twelve-week review: blood pressure and lipids after a gout flare on hydrochlorothiazide; switch to losartan. **S**
